

Claims

1. A cancer metastasis inhibitor comprising a substance which inhibits an activity of insulin-like growth factor-I (IGF-I) and insulin-like growth factor-II (IGF-II) as an active ingredient.

2. The inhibitor according to claim 1, wherein the substance is selected from a group consisting of the following (a) to (e).

(a) an antibody or an antibody fragment which specifically binds to IGF-I and IGF-II and inhibits the activity of IGF-I and IGF-II;

(b) a composition comprising an antibody or an antibody fragment which specifically binds to IGF-I and inhibits the activity of IGF-I and an antibody or an antibody fragment which specifically binds to IGF-II and inhibits the activity of IGF-II;

(c) a composition comprising combination of a composition comprising an antibody or an antibody fragment which specifically binds to IGF-I and inhibits the activity of IGF-I and a composition comprising an antibody or an antibody fragment which specifically binds to IGF-II and inhibits the activity of IGF-II;

(d) a conjugate of an antibody or an antibody fragment which specifically binds to IGF-I and inhibits the activity of IGF-I with an antibody or an antibody fragment which specifically binds to IGF-II and inhibits the activity of IGF-II; and

(e) a conjugate of any of the above (a) to (d) with the other molecules.

3. The inhibitor according to claim 2, wherein the

antibody is a monoclonal antibody.

4. The inhibitor according to claim 2 or 3, wherein the antibody fragment is an antibody fragment selected from the group consisting of Fab, Fab', F(ab')₂, single-chain antibody (scFv), dimerized variable region (Diabody), disulfide-stabilized variable region (dsFv) and CDR-containing peptide.